927 Shares in IQVIA Holdings Inc. (NYSE:IQV) Bought by Team Hewins LLC

Team Hewins LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 927 shares of the medical research company’s stock, valued at approximately $214,000.

Several other institutional investors have also added to or reduced their stakes in the business. Private Advisor Group LLC boosted its stake in IQVIA by 1.2% in the 3rd quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock worth $948,000 after purchasing an additional 56 shares in the last quarter. NBC Securities Inc. purchased a new stake in shares of IQVIA during the third quarter valued at $541,000. Victory Capital Management Inc. increased its position in shares of IQVIA by 3.4% in the 3rd quarter. Victory Capital Management Inc. now owns 105,163 shares of the medical research company’s stock valued at $20,691,000 after acquiring an additional 3,413 shares during the period. Versor Investments LP purchased a new position in IQVIA in the 3rd quarter worth $525,000. Finally, Illinois Municipal Retirement Fund lifted its position in IQVIA by 26.6% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 12,141 shares of the medical research company’s stock worth $2,389,000 after acquiring an additional 2,552 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 1.1 %

Shares of IQVIA stock opened at $229.60 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The company has a market cap of $41.83 billion, a P/E ratio of 31.37, a price-to-earnings-growth ratio of 2.09 and a beta of 1.52. The firm has a 50-day simple moving average of $237.13 and a two-hundred day simple moving average of $228.93.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research reports. Evercore ISI cut their price objective on IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a report on Friday, May 3rd. SVB Leerink began coverage on shares of IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target on the stock. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, Robert W. Baird reduced their target price on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a report on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $257.57.

Insider Buying and Selling

In other news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.